NASDAQ:OMER Omeros (OMER) Stock Price, News & Analysis → Hurry! Buy this stock before the Robinhood traders do! (From Traders Agency) (Ad) Free OMER Stock Alerts $3.81 -0.04 (-1.04%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$3.71▼$3.8550-Day Range$3.04▼$4.2052-Week Range$0.92▼$7.59Volume235,149 shsAverage Volume368,954 shsMarket Capitalization$220.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Omeros alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Omeros Stock (NASDAQ:OMER)Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Read More OMER Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMER Stock News HeadlinesJune 4, 2024 | businesswire.comOmeros Announces Webcast Details for Annual Meeting of ShareholdersJune 4, 2024 | americanbankingnews.comOmeros (NASDAQ:OMER) Earns Hold Rating from Needham & Company LLCJune 3, 2024 | businesswire.comOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028May 19, 2024 | marketwatch.comOmeros Shares Drop 20% After Wider 1Q LossMay 16, 2024 | msn.comOmeros Corporation (NASDAQ:OMER) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comOmeros plunges 20% following Q1 report, drug updateMay 16, 2024 | finance.yahoo.comQ1 2024 Omeros Corp Earnings CallMay 16, 2024 | finance.yahoo.comOmeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...May 15, 2024 | investorplace.comOMER Stock Earnings: Omeros Misses EPS for Q1 2024May 15, 2024 | businesswire.comOmeros Corporation Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comOmeros Q1 2024 Earnings PreviewMay 10, 2024 | businesswire.comOmeros Corporation to Announce First Quarter Financial Results on May 15, 2024May 9, 2024 | finance.yahoo.comOmeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid CongressApril 29, 2024 | msn.comCharges laid after alleged Gold Coast cold calling scam leads to $1.5m lossApril 17, 2024 | msn.comOmeros (OMER) Price Target Increased by 230.77% to 43.86April 2, 2024 | marketwatch.comOmeros Shares Down 6% on Swing to 4Q LossApril 2, 2024 | finance.yahoo.comOmeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 Omeros Corp Earnings CallApril 1, 2024 | investorplace.comOMER Stock Earnings: Omeros Misses EPS for Q4 2023April 1, 2024 | finance.yahoo.comOmeros Corporation Reports Fourth Quarter and Year-End 2023 Financial ResultsApril 1, 2024 | finance.yahoo.comOmeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial ResultsMarch 27, 2024 | businesswire.comOmeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024March 19, 2024 | finance.yahoo.comOMER Aug 2024 3.000 putMarch 3, 2024 | finance.yahoo.comOMER Aug 2024 5.000 putMarch 1, 2024 | gurufocus.comOmeros Corporation - Special Call TranscriptSee More Headlines Receive OMER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/12/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OMER CUSIP68214310 CIK1285819 Webwww.omeros.com Phone(206) 676-5000Fax206-676-5005Employees198Year Founded1994Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,916.35% Return on Assets-39.01% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-9.53Miscellaneous Outstanding Shares57,940,000Free Float51,628,000Market Cap$220.75 million OptionableOptionable Beta1.36 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Gregory A. Demopulos M.D. (Age 65)Co-Founder, Chairman, CEO & President Comp: $1.79MMr. Michael A. Jacobsen (Age 66)Chief Accounting Officer, VP of Finance & Treasurer Comp: $518.6kMr. Peter B. Cancelmo J.D. (Age 45)VP, General Counsel & Corporate Secretary Comp: $503.24kDr. Pamela Pierce Palmer M.D. (Age 61)Ph.D., Co-Founder Dr. George A. Gaitanaris M.D. (Age 67)Ph.D., Chief Scientific Officer & VP of Science Mr. Peter W. Williams (Age 56)Vice President of Human Resources Dr. Catherine A. Melfi Ph.D. (Age 65)Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems Ms. Nadia Dac (Age 54)VP & Chief Commercial Officer Dr. Andreas Grauer M.D. (Age 63)VP & Chief Medical Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRVanda PharmaceuticalsNASDAQ:VNDAAssembly BiosciencesNASDAQ:ASMBCara TherapeuticsNASDAQ:CARACumberland PharmaceuticalsNASDAQ:CPIXView All CompetitorsInsiders & InstitutionsVirtu Financial LLCSold 18,983 shares on 5/20/2024Ownership: 0.017%Comerica BankBought 5,000 shares on 5/17/2024Ownership: 0.052%Vanguard Group Inc.Bought 81,348 shares on 5/10/2024Ownership: 5.610%Oppenheimer & Co. Inc.Bought 24,503 shares on 5/7/2024Ownership: 0.042%SG Americas Securities LLCSold 18,123 shares on 5/7/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions OMER Stock Analysis - Frequently Asked Questions Should I buy or sell Omeros stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares. View OMER analyst ratings or view top-rated stocks. How have OMER shares performed in 2024? Omeros' stock was trading at $3.27 at the beginning of the year. Since then, OMER stock has increased by 16.5% and is now trading at $3.81. View the best growth stocks for 2024 here. When is Omeros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our OMER earnings forecast. How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) released its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.13. What guidance has Omeros issued on next quarter's earnings? Omeros issued an update on its first quarter 2024 earnings guidance on Monday, April, 1st. The company provided earnings per share (EPS) guidance of -0.630--0.580 for the period. The company issued revenue guidance of -. What is Gregory A. Demopulos' approval rating as Omeros' CEO? 17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees. What other stocks do shareholders of Omeros own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX). Who are Omeros' major shareholders? Omeros' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.61%), Susquehanna Fundamental Investments LLC (0.27%), Simplex Trading LLC (0.00%), BNP Paribas Financial Markets (0.05%), Comerica Bank (0.05%) and Oppenheimer & Co. Inc. (0.04%). Insiders that own company stock include Arnold C Hanish, Gregory A Md Demopulos and Peter A Md Demopulos. View institutional ownership trends. How do I buy shares of Omeros? Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Omeros have any subsidiaries? The following companies are subsidiares of Omeros: Nura.Read More This page (NASDAQ:OMER) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersYour Special Report - Top 7 Summer StocksSummer is almost Here! I would like to give you a special report that could help boost your portfolio this sum...StockEarnings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.